the evolution of her2 targeting in metastatic breast breast cancer
Published 1 year ago • 346 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
3:32
sequencing novel her2-targeted therapies in metastatic breast cancer
-
0:45
the evolution of her2-low breast cancer from primary to recurrence
-
0:59
sequencing her2-targeted therapies in breast cancer
-
2:24
current and future her2 , hr- metastatic breast cancer treatment approaches
-
1:20
dr. hurvitz on the evolution of treatment in metastatic her2 breast cancer
-
2:15
the evolution of advanced breast cancer management
-
2:59
unlocking breast cancer: essential information for every woman (3 minutes)
-
4:45
evolving role of her2-targeted therapy in breast cancer
-
1:29
tuxedo-1: trastuzumab deruxtecan for the treatment of her2-positive breast cancer brain metastases
-
2:49
neratinib, trastuzumab fulvestrant for her2-mutant, hr , metastatic breast cancer
-
0:35
key challenge associated with the management of hr /her2- breast cancer
-
3:19
study of targeted therapy for her2-positive metastatic breast cancer
-
56:54
10/16/2015: "evolution of targeted therapies in breast cancer: new opportunities for cure"
-
1:55
advances in treatments for her2-positive metastatic breast cancer
-
2:15
treatment strategies for her2 metastatic breast cancer
-
4:53
comparing therapy benefit from initially her2 positive or negative metastatic breast cancer patients
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
2:22
sequencing therapies in her2 breast cancer